JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
128.36
+1.60 (+1.26%)
As of 12:36PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close126.76
Open126.62
Bid128.41 x 100
Ask128.43 x 200
Day's Range126.66 - 128.51
52 Week Range122.15 - 148.32
Volume2,220,953
Avg. Volume8,031,553
Market Cap344.344B
Beta0.59
PE Ratio (TTM)270.80
EPS (TTM)0.47
Earnings DateJul 17, 2018
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target Est145.10
Trade prices are not sourced from all markets
  • How Analysts Rate JNJ after 1Q18 Earnings
    Market Realist2 hours ago

    How Analysts Rate JNJ after 1Q18 Earnings

    As discussed earlier, Johnson & Johnson reported a 12.6% increase in revenues to $20.0 million in 1Q18 as compared to $17.8 million in 1Q17. The increase included 8.4% growth in revenues at constant exchange rates and a 4.2% positive impact of foreign exchange.

  • PR Newswire2 hours ago

    Johnson & Johnson Announces Dividend Increase of 7.1%

    NEW BRUNSWICK, N.J., April 26, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share.  The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J. "In recognition of our 2017 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the quarterly dividend for the 56th consecutive year," said Alex Gorsky, Chairman and Chief Executive Officer of the company. At the new rate, the indicated dividend on an annual basis is $3.60 per share compared to the previous rate of $3.36 per share.  The next quarterly dividend is payable on June 12, 2018 to shareholders of record as of the close of business on May 29, 2018.

  • Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
    Zacks2 hours ago

    Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses

    Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.

  • Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
    Market Realist2 hours ago

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb (BMY) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues in 1Q18. It reported EPS of $0.94 on revenues of $5.2 billion in 1Q18 today, compared to analysts’ estimates for EPS of $0.85 on revenues of $5.2 billion.

  • What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?
    Market Realist4 hours ago

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    As discussed earlier, Johnson & Johnson (JNJ) reported revenue growth of 12.6% in its 1Q18 revenues to $20.0 billion.

  • What Wall Street Analysts Estimate for Johnson & Johnson
    Market Realist5 hours ago

    What Wall Street Analysts Estimate for Johnson & Johnson

    Johnson & Johnson (JNJ) surpassed EPS (earnings per share) and revenue estimates in 1Q18. For 1Q18, Johnson & Johnson reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against the estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q18.

  • Reuters13 hours ago

    Johnson & Johnson wins appeal to overturn $151 million hip implant verdict

    The 5th U.S. Circuit Court of Appeals said two of the plaintiffs' defective marketing claims were legally insufficient and a new trial was required overall in the case because of a judge's evidentiary rulings and "deceptions" by their lawyer. U.S. Circuit Judge Jerry Smith, writing for the three-judge panel, said U.S. District Judge Ed Kinkeade in Dallas erred in allowing the hip implant recipients' lawyers to present certain "inflammatory character evidence" about J&J. Smith said the "most problematic evidence" were bribes J&J paid to "henchmen" of Saddam Hussein in Iraq, allegations stemming from the company's agreement in 2011 to pay $70 million to resolve U.S. foreign bribery probes.

  • Reuters13 hours ago

    J&J wins appeal to overturn $151 million hip implant verdict

    Johnson & Johnson on Wednesday secured a favorable U.S. appellate court ruling, overturning a verdict that had awarded $151 million to five people who blamed injuries they suffered on the company's Pinnacle hip implant devices. The 5th U.S. Circuit Court of Appeals said two of the plaintiffs' defective marketing claims were legally insufficient and a new trial was required overall in the case because of a judge's evidentiary rulings and "deceptions" by their lawyer. U.S. Circuit Judge Jerry Smith, writing for the three-judge panel, said U.S. District Judge Ed Kinkeade in Dallas erred in allowing the hip implant recipients' lawyers to present certain "inflammatory character evidence" about J&J.

  • J&J Gets Court to Throw Out $151 Million Artificial Hip Verdict
    Bloomberg18 hours ago

    J&J Gets Court to Throw Out $151 Million Artificial Hip Verdict

    Johnson & Johnson persuaded an appeals court to throw out a $151 million award against the company over its Pinnacle artificial hips in a ruling that will affect thousands of lawsuits over the devices. A judge’s error in allowing hip recipients’ lawyers to use “highly prejudicial” evidence about bribes paid by officials of J&J units in their 2016 case mandated the jury verdict’s reversal, the New Orleans-based appeals court concluded Wednesday. Mark Lanier, the plaintiffs’ lawyer, said Wednesday he’s ready to retry the case immediately.

  • InvestorPlaceyesterday

    Buy the Post-Earnings Lull from Johnson & Johnson

    It could have been worse for Johnson & Johnson (NYSE:JNJ) last quarter, although given the slightly bearish response from JNJ stock last week, the market also thinks it could have been better. Better still, the company’s got a plan to further beef up its research and development without taking anything away from shareholders. For the quarter ending in March, Johnson & Johnson turned $20.0 billion in revenue into an operating profit of $2.06 per share.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realistyesterday

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18
    Market Realistyesterday

    Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18

    In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.

  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realistyesterday

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realistyesterday

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
    Zacksyesterday

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realistyesterday

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realistyesterday

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
    Zacks2 days ago

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

  • Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
    PR Newswire2 days ago

    Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference

    NEW BRUNSWICK, N.J. , April 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9 th , at The InterContinental ...

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist2 days ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
    Market Realist2 days ago

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist3 days ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Here’s why Amazon won’t go into pharma: hedge fund billionaire
    Yahoo Finance Video2 days ago

    Here’s why Amazon won’t go into pharma: hedge fund billionaire

    Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.